SION-719 Misses CFTR-Activity Endpoint in Phase IIa

Company: Sionna Therapeutics · Event Type: Clinical/Regulatory Signal · Product/Asset: SION-719 · Subject: Cystic Fibrosis · Event Date: August 10, 2026 Summary Sionna Therapeutics reported that adding the NBD1 stabilizer SION-719 to Trikafta for 14 days did not achieve the Phase IIa trial’s key activity…